, , ,

Briokem 50

Composition:

  • Brivaracetam 50 mg
    Therapeutic Class:

  • Antiepileptic / Anticonvulsant
    Schedule: Schedule H1 (Prescription Only + Special Monitoring Required)

Briokem 50 contains Brivaracetam, a novel antiepileptic drug (AED) that acts as a high-affinity synaptic vesicle protein 2A (SV2A) ligand, designed for adjunctive treatment of focal seizures in adults and adolescents. It offers a faster onset of action, improved CNS tolerability, and fewer behavioral side effects compared to traditional AEDs.

Usage of Briokem 50

Briokem 50 is indicated for:

  • Focal onset seizures (partial seizures) with or without secondary generalization

  • Adjunct therapy in patients with epilepsy not fully controlled on current regimen

  • Can also be used in generalized epilepsy (off-label in some settings)


Mechanism of Action

Brivaracetam selectively binds to SV2A, a synaptic vesicle protein involved in neurotransmitter release modulation, resulting in:

  • Suppression of neuronal hyperexcitability

  • Inhibition of epileptic activity spread

  • Improved seizure control with minimal sedation

Compared to levetiracetam, Brivaracetam has 20x higher affinity for SV2A and lower risk of irritability, agitation, or mood changes.


Key Benefits

Rapid onset of antiepileptic action
✅ Improved behavioral and psychiatric tolerability
✅ Lower incidence of drowsiness, dizziness, and fatigue
✅ Safe as add-on therapy with most AEDs
✅ No need for titration in most patients — easy to initiate


Common Side Effects

  • Somnolence or dizziness (dose-dependent)

  • Fatigue

  • Nausea or irritability (mild and self-limiting)

  • Rare: Mood swings, aggression, suicidal thoughts (monitor closely)


Precautions

  • Use cautiously in patients with depression or psychiatric history

  • May cause drowsiness or impaired driving ability

  • Monitor behavior, especially during initial weeks of therapy

  • Avoid abrupt discontinuation to prevent withdrawal seizures

  • Dose adjustment may be required in severe hepatic impairment


Drug Interactions

  • Minimal drug interactions due to limited CYP metabolism

  • Can be safely co-administered with most AEDs (lamotrigine, valproate, carbamazepine, etc.)

  • Avoid use with alcohol or CNS depressants

  • May slightly interact with rifampicin, carbamazepine epoxide (reduce efficacy)


Dosage and Administration

  • Usual dose: 50 mg twice daily (can be increased to 100 mg BID if needed)

  • Can be taken with or without food

  • No need for slow titration in most cases

  • Do not crush or split the tablet


Storage

  • Store at room temperature below 25°C

  • Protect from moisture and direct sunlight

  • Keep out of reach of children


Patient Counseling Points

  • Take the medication at the same time each day

  • Do not stop abruptly — consult physician if side effects occur

  • Inform your doctor about any mood changes, irritability, or suicidal thoughts

  • Avoid driving or operating machinery until the effect is known

  • Regular follow-ups for seizure control and side effect monitoring are important

Review My Order

0

Subtotal